The Attorney General provided a detailed, lengthy analysis to the Nebraska HHS lead, declaring that based on the available data, they “do not find clear and convincing evidence that a physician who first obtains informed consent and then utilizes ivermectin or hydroxychloroquine after COVID-19 violates UCA.”
Large reductions in Covid-19 deaths are possible using ivermectin.
Using ivermectin early may reduce the numbers progressing to severe disease.
Ivermectin is low cost.
The authors concluded based on this extensive review that ivermectin actually reduced the risk of death compared with no ivermectin (average risk ratio 0.38, 95% CI 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence).
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Medical experts from around the world joined together to present the very latest real world research on repurposing ivermectin that has the ability to transform global efforts to fight the pandemic. Mr. Andrew Bryant provides an overview of ongoing trials and what they may add to the evidence base.
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.
In an interview with Alan Jones, Craig Kelly MP discusses the vaccine rollout mishaps and yet again, rightfully points out the myriad of medical specialists around the world who support the use of ivermectin for the prophylaxis and treatment of their Covid-19 patients with the backup of extensive positive data.
The World Health Organization and National Institutes of Health now have all the data they need to recommend ivermectin to prevent and treat COVID-19. And those who want to end this pandemic now, for all countries rich and poor, should welcome that move.
We discussed the Surgisphere debacle and other stories of “engineered research” during the pandemic, most of which I am currently preparing articles about.
Suppose that we want to rig a medical study despite the participation of mostly or entirely caring doctors and researchers with unimpeachable character and credentials.
While HCQ looks very safe overall for COVID-19 patients, it looks safest when used as a prophylactic or therapeutic for early stage COVID-19 patients, once again affirming the Primary HCQ Hypothesis as the strongest version of the HCQ Hypothesis.
The group that didn’t take the ivermectin, over 3 months it was fifty-eight percent. Fifty-eight percent of those doctors, nurses and orderlies contracted coronavirus.
In the 788 group, the same doctors, nurses and orderlies across the 4 hospitals, the number of infections that they had, was zero. ZERO, that were treated with ivermectin.
The Hydroxychloroquine Hypothesis: That there is some appropriate dosage of hydroxychloroquine, alone or in some combination with other medication, that successfully prevents some COVID-19 cases (PrEP/PEP) or treats some COVID-19 sufferers (Early/Late/Critical).
Remaining entirely unblemished after a year of trials and observations, the current evidence in favor of the Primary HCQ Hypothesis fully validates the HCQ Hypothesis. The logic is so simple that it almost feels like your livelihood would have to be on the line to deny it.
This is now one of the most well-studied treatments in the history of medicine, and the evidence is overwhelming. The chance that these results could occur at random is approximately 1 in 208 quadrillion. That is, p = 0.000000000000048. Having read a few thousand research papers, I have never before seen a p-value this low in the testing of medicine.
The science shows that ivermectin works. Over 40 randomized trials and observational studies from around the world attest to its efficacy against the novel coronavirus. Meta-analyses by four separate research groups, including ours, found an average reduction in mortality of between 68%-75%. And 10 of 13 randomized controlled trials found statistically significant reductions in time to viral clearance, an effect not associated with any other COVID-19 therapeutic. Furthermore, ivermectin has an unparalleled safety record and low cost, which should negate any fears or resistance to immediate adoption.
“As a clinician, you should know that Covid-19 outpatient disease is viral replication, vs hospitalized disease which is florid pneumonia. These are absolutely different conditions and studies of the treatment of one cannot be extrapolated to the treatment of the other.
This massive body of evidence, summarized by the Cochrane Library, demonstrates that well-conducted hydroxychloroquine observational studies on average, produce very similar associations as the corresponding RCTs.
More than 30 trials across the world found that ivermectin causes ‘repeated, consistent, large magnitude improvements in clinical outcomes’ at all stages of the disease. The peer-reviewed study, to be published in the US journal Frontiers of Pharmacology, says the evidence is so strong that the drug – used to treat head lice and scabies – should become a standard therapy everywhere, so hastening the global recovery.
HCQ is a zinc ionophore, meaning it shuttles zinc into the cell, and there’s compelling evidence to suggest the primary benefit of the HCQ protocol actually comes from the zinc, which effectively inhibits viral replication.
American Journal of Medicine announces peer-reviewed early outpatient treatment protocol for Covid19 including hydroxychloroquine. Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal. In the absence of clinical trials and guidelines, with hospitalizations and mortality mounting, it is prudent to deploy treatment for COVID-19 based on pathophysiological principles.
A leading U.S. medical journal announced the medicine hydroxychloroquine can effectively treat the coronavirus.
Source: Fox News Dr. Harvey Risch of the Yale School of Public Health and physician Dr. Scott Jensen join ‘The Ingraham Angle’ to discuss the
Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew
Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison, these are the total dose in the first two days
HCQ is effective for COVID-19. The chance that an ineffective treatment generated results as positive as the 187 studies to date is 1 in 5 quadrillion (p = 0.00000000000000019).
Early SMDT (sequenced multidrug therapy) should be a standard practice in high risk & severely symptomatic acute COVID-19 patients at the onset of illness.
Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version 28, December 4, 2020) • HCQ is effective for COVID-19.
Source: The Blaze Author: CHRIS PANDOLFO A peer-reviewed study analyzing the effectiveness of a triple drug cocktail including hydroxychloroquine in treating COVID-19 patients found that the treatment
Source: News Max Author: By Brian Trusdell Photo: Getty The anti-malarial drug promoted by the US President as a treatment for COVID-19 — and derided by
Source: BioSpace SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 03, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel
Source: HCQmeta.com • HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 132 studies to date is
Source:The Conservative Woman A GROUNDBREAKING study of early treatment of Covid-19 in high-risk patients with ‘The Zelenko Protocol’ (zinc plus low-dose hydroxychloroquine and azithromycin) resulting in
Source: MedRxiv. Full Study in PDF here Xabier Garcia-Albeniz, Julia Del Amo, Rosa Polo, Jose Miguel Morales Asencio, Miguel A HernanmedRxiv 2020.09.29.20203869; doi: https://doi.org/10.1101/2020.09.29.20203869 Abstract Background: There is disagreement about whether hydroxychloroquine (HCQ) is effective as prophylaxis
Source: The Guardian Author: Melissa Davey One of the world’s leading medical journals, the Lancet, has reformed its editorial policies following a shocking case of
Source: Clinical & Translational Science Marinella Lauriola Arianna Pani Giovanbattista IppolitiAndrea MortaraStefano MilighettiMarjieh MazenGianluca PerseghinDaniele PastoriPaolo GrossoFrancesco Scaglione doi:10.1111/cts.12860 Full study here. Abstract Conflicting evidence
Source: c19 Study A live and ongoing index of study data from around the world documenting the use of hydroxychloroquine in treatment at various stages
Source: Research Gate Conclusions Hydroxychloroquine has been shown to have consistent clinical efficacy for COVID-19 when it is used early in the outpatient setting, and
Source: Open Letter Concerns regarding the misinterpretation of statistical hypothesis testing in clinical trials for COVID-19 This letter is an expression of concern that a
Source: c19study.com The studies continue to roll out, and there has been very positive results in pre and post exposure as well as early treatment
Source: IC Journal Citation: Hong KS, Jang JG, Hur J, Lee JH, Kim HN, Lee W, Ahn JH. Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory
Source: Zendo In an open letter to MR Mehra, SS Desai, F Ruschitzka, and AN Patel, authors of “Hydroxychloroquine or chloroquine with or without a
